QuidelOrtho Corp (QDEL) FY2025 10-K Annual Report
QuidelOrtho Corp (QDEL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
QuidelOrtho Corp FY2025 10-K Analysis
Business Overview
- • Core business model: global diagnostics provider specializing in immunoassay, molecular testing, clinical chemistry, transfusion medicine, and POC solutions
- • Initiated wind-down of U.S. donor screening portfolio (VIP platform, microplate assays) starting Feb 2024, expected substantially complete by mid-2026
- • New emphasis on advancing digital solutions with launch of QuidelOrtho RESULTS MANAGER and planned 2026 releases of automation and informatics products
- • R&D spend $186.2M in 2025, down from $218.7M in 2024, reflecting project phase transitions and continued innovation investment
- • Customer service innovation highlighted by being first medical device company awarded global ISO Excellence Services Label in EMEA region
Management Discussion & Analysis
- • Revenue $2,730.2M FY25, down 2% YoY from $2,782.9M; FY24 down 7% YoY from $2,997.8M, COVID-19 product declines primary driver
- • Operating margin approx. 20.1% FY25 (Operating expenses $1,488.9M = 54.5% of revenue), cost of sales 53.3% vs 53.8% in FY24; margin benefit from cost savings initiatives
- • Best segment growth: EMEA revenue up 7% to $360.7M, Adjusted EBITDA up 78% to $82.6M; worst segment: Donor Screening revenue down 54% to $52.6M due to U.S. wind-down
- • Operating cash flow pressures from restructuring charges: Restructuring charges $263.6M in FY25 vs $127.2M in FY24; buybacks/dividends details not provided; capital spending not detailed
- • Outlook cautious: Ongoing COVID/endemic dynamics, competitive pressures, pricing pressures, geopolitical tariffs risks; restructuring and strategic refocus ongoing to improve financials
Risk Factors
- • Legal/regulatory risk: FDA EUA approvals and compliance with anti-bribery and data privacy laws impacting product commercialization and operations
- • Geopolitical/macro risk: April 2025 U.S. tariffs on imports from U.K., Canada, Mexico, China causing incremental supply chain and shipping costs
- • Operational/supply chain risk: Concentration in California facilities near earthquake/fire faults posing disruption risk to manufacturing and product delivery
- • Competitive risk: Distributors developing own competitive products and exclusive agreements with rivals threatening key sales channels
- • Financial risk: Customer concentration with significant revenues from few distributors; loss would materially disrupt sales and financial results
QuidelOrtho Corp FY2025 Key Financial MetricsXBRL
Revenue
$2.7B
▼ -1.9% YoY
Net Income
-$1.1B
▲ +44.8% YoY
Operating Margin
-33.7%
▲ +3679bp YoY
Net Margin
-41.5%
▲ +3228bp YoY
ROE
-58.9%
▲ +982bp YoY
Total Assets
$5.8B
▼ -10.2% YoY
EPS (Diluted)
$-16.69
▲ +45.4% YoY
Operating Cash Flow
$105M
▲ +26.7% YoY
Source: XBRL data from QuidelOrtho Corp FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on QuidelOrtho Corp
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.